Pipeline

Rivoceranib (Apatinib) is a small molecule drug candidate which has been approved in China and has completed Phase 1/2A development in the US. It is being developed for the treatment of certain solid tumor cancers including Metastatic Gastric Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Metastatic Breast Cancer, and Non-Small Cell Lung Cancer.

Learn More About Rivoceranib